Nivolumab induces seven-year sustained remission in a patient with advanced PD-L1-positive lung adenocarcinoma: a case report
{{output}}
Objective: To summarize the clinical experience of a patient with advanced non-small cell lung cancer (NSCLC) who achieved long-term survival after treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab. ... ...
